Evidence map›Paper›PMID 39415917›Full record

ArticleEJHaem2024

Mutant NPM1 marginally impacts ribosome footprint in acute myeloid leukemia cells.

Lorenzo Brunetti, Giulia Pianigiani, Michael C Gundry, Margaret A Goodell, Brunangelo Falini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lorenzo BrunettiDepartment of Clinical and Molecular Sciences Hematology, Università Politecnica delle Marche Ancona Italy.ORCID https://orcid.org/0000-0003-2624-8576
Giulia PianigianiDepartment of Medicine and Surgery Hematology, Center for Hemato-Oncological Research (CREO) University of Perugia Perugia Italy.ORCID https://orcid.org/0000-0003-0851-1473
Michael C GundryStem Cell and Regenerative Medicine Baylor College of Medicine Houston Texas USA.
Margaret A GoodellStem Cell and Regenerative Medicine Baylor College of Medicine Houston Texas USA.
Brunangelo FaliniDepartment of Medicine and Surgery Hematology, Center for Hemato-Oncological Research (CREO) University of Perugia Perugia Italy.ORCID https://orcid.org/0000-0002-7198-5965

Funding

DNMT3A in Development of Hematologic MalignanciesR01CA183252 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL · 2014 to 2026
$7.1M
NCI NIH HHS R01 CA183252
6 · The paper itself

Abstract

Background: Methods: Here, we performed ribosome footprint profiling (Ribo-seq) and bulk messenger RNA (mRNA) sequencing in two Results and discussion: Incubation of degron cells with the small compound dTAG-13 enables highly specific degradation of NPM1c within 4 hours. As expected, RNA-sequencing data showed early loss of homeobox gene expression following NPM1c degradation, confirming the reliability of our model. In contrast, Ribo-seq data showed negligible changes in the ribosome footprint in both cell lines, implying that the presence of NPM1c does not influence ribosome abundance and positioning on mRNA. While it is predictable that NPM1c exerts its leukemogenic activity at multiple levels, ribosome footprint does not seem influenced by the presence of mutant NPM1.

Indexed as

acute leukemiacell biologytranscription

Identifiers

PMID39415917
PMCPMC11481009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.